



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Frontiers Production Office  
✉ production.office@frontiersin.org

SPECIALTY SECTION  
This article was submitted to  
Cancer Immunity  
and Immunotherapy,  
a section of the journal  
Frontiers in Immunology

RECEIVED 02 December 2022  
ACCEPTED 02 December 2022  
PUBLISHED 12 December 2022

CITATION  
Frontiers Production Office (2022)  
Erratum: Real-world landscape  
transition of death causes in the  
immunotherapy era for metastatic  
non-small cell lung cancer.  
*Front. Immunol.* 13:1114331.  
doi: 10.3389/fimmu.2022.1114331

COPYRIGHT  
© 2022 Frontiers Production Office. This  
is an open-access article distributed  
under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction  
in other forums is permitted, provided  
the original author(s) and the  
copyright owner(s) are credited and  
that the original publication in this  
journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is  
permitted which does not comply with  
these terms.

# Erratum: Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

death cause analysis, immunotherapy, non-small cell lung cancer, metastatic disease, real world data

## An Erratum on

### Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer

By Wu Y, Yao Z, Zhang J, Han C, Kang K and Zhao A (2022) *Front. Immunol.* 13:1058819. doi: 10.3389/fimmu.2022.1058819

Due to a production error, there was a mistake on the first line of the Methods section where the number of patients with metastatic NSCLC was incorrectly captured as “298,48patients” when it should have been “298,485 patients”.

A correction has been made to the Abstract section, subsection Methods:

“In this cohort study, 298,485 patients with metastatic NSCLC diagnosed between 2000 and 2018 were identified from the Surveillance, Epidemiology, and End Results Program. Unsupervised clustering with Bayesian inference method was performed for all patients’ death causes, which separated them into two death patterns: the pre-immunotherapy era group and the immunotherapy era group. Relative risk (RR) of each death cause between two groups was estimated using Poisson regression. Reduced death risk as survival time was calculated with locally weighted scatterplot smooth (Lowess) regression.”

The publisher apologizes for this mistake.

The original version of this article has been updated.